MYGN

Myriad Genetics Inc. - Form 10-Q Summary

Business Context and Reporting Period

This filing covers the quarterly period ended March 31, 2003, for Myriad Genetics, Inc., a biopharmaceutical company focused on therapeutic and predictive medicine products. The company operates two primary segments: Predictive Medicine (testing for disease predisposition) and Research (gene discovery, sequencing, and therapeutic development). As of May 1, 2003, the company had 27,019,508 shares of common stock outstanding.

Key Financial Metrics

Segment Performance (Nine Months Ended Mar 31, 2003):

• Predictive Medicine Revenue: $25,329 (Gross Margin: 63%)
• Research Revenue: $23,288
• Research & Development Expense: $34,217
• Selling, General & Administrative Expense: $24,795

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 23% for the three months and 22% for the nine months compared to the prior year periods. Predictive medicine revenue grew 28% (quarterly) and 32% (nine months), driven by increased sales and marketing efforts. Research revenue grew 17% (quarterly) and 13% (nine months), largely due to collaborations with DuPont and Abbott Laboratories.
• Expense Increases: Operating losses widened significantly. R&D expenses rose 26% (quarterly) and 34% (nine months) due to clinical trials for prostate cancer and Alzheimer's disease. SG&A expenses increased 32% (quarterly) and 41% (nine months) due to direct-to-consumer marketing campaigns and personnel growth.
• Liquidity: Cash and marketable securities increased by $4.9 million (4%) year-over-year, primarily due to a November 2002 public offering of common stock yielding $57.2 million in net proceeds.
• Interest Income: Declined 35% (quarterly) and 49% (nine months) due to falling interest rates.

Outlook, Risks, and Management Commentary

Outlook: Management expects to incur losses for at least the next several years due to the expansion of drug discovery, clinical trials, and predictive medicine product launches. The company believes it has adequate capital resources to maintain operations for at least the next two years.

Key Developments:

• Therapeutics: Lead candidate Flurizan (MPC-7869) for prostate cancer is in a large multi-center clinical trial. An IND application for Alzheimer's disease treatment is in progress.
• Predictive Medicine: Continued commercialization of BRACAnalysis (breast/ovarian cancer) and COLARIS (colon cancer) products.

Risks and Contingencies:

• Regulatory & Clinical Risk: No assurance that clinical trials will result in marketable products or that regulatory approval will be obtained.
• Capital Requirements: Future capital needs are substantial and dependent on the progress of preclinical/clinical activities and the ability to secure financing.
• Accounting Changes: The company is evaluating the impact of FASB Interpretation No. 46 regarding the consolidation of variable interest entities.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $45.1 million net cash used in operating activities over the nine-month period against current cash reserves of ~$130 million.
• Revenue Recognition: Review the "percentage-of-completion" methodology used for research collaboration revenues, as actual results may vary significantly from estimates.
• Clinical Trial Progress: Monitor the status of the Flurizan (MPC-7869) clinical trials for prostate cancer and Alzheimer's disease, as these are critical to future therapeutic revenue.
• Stock-Based Compensation: Note that pro forma net loss would be significantly higher ($36.9 million for nine months) if stock-based compensation were expensed under FAS 123.
• Deferred Revenue: Investigate the $10.5 million decrease in deferred revenue, indicating a shift from unearned to recognized revenue from collaborative agreements.